Dissolution enhancement of olmesartan medoxomil through polymer-based surface solid dispersion and solidified surfactant techniques
This study aims to formulate Olmesartan medoxomil (OM) into oral fast-dissolving tablets (FDTs) to improve its solubility and bioavailability via two different techniques; The polymer-based surface solid dispersion (SSD) technique and the solidified surfactant (SS) technique. In the first technique, two polymers were used; polyvinylpyrrolidone (PVP K90) and Poloxamer 407 (Pluronic®F127), while in the second technique the liquid Tween 80 was solidified by adsorption onto Aeroperl®300. The pre-compression and post-compression parameters of the obtained formulations were assessed. The best formulations were subjected to a taste masking evaluation and a short-term stability study. The results demonstrated that, in comparison to the pure drug, the proportion of drug released from each of the prepared FDTs considerably increased. Results of the stability studies showed that the chosen drug formulations remained stable throughout the storage period.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Pakistan journal of pharmaceutical sciences - 35(2022), 6 vom: 15. Nov., Seite 1481-1493 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Daihom, Baher A [VerfasserIn] |
|---|
| Themen: |
106392-12-5 |
|---|
| Anmerkungen: |
Date Completed 16.02.2023 Date Revised 16.02.2023 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM352963808 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352963808 | ||
| 003 | DE-627 | ||
| 005 | 20231226054920.0 | ||
| 007 | tu | ||
| 008 | 231226s2022 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM352963808 | ||
| 035 | |a (NLM)36789807 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Daihom, Baher A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dissolution enhancement of olmesartan medoxomil through polymer-based surface solid dispersion and solidified surfactant techniques |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2023 | ||
| 500 | |a Date Revised 16.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This study aims to formulate Olmesartan medoxomil (OM) into oral fast-dissolving tablets (FDTs) to improve its solubility and bioavailability via two different techniques; The polymer-based surface solid dispersion (SSD) technique and the solidified surfactant (SS) technique. In the first technique, two polymers were used; polyvinylpyrrolidone (PVP K90) and Poloxamer 407 (Pluronic®F127), while in the second technique the liquid Tween 80 was solidified by adsorption onto Aeroperl®300. The pre-compression and post-compression parameters of the obtained formulations were assessed. The best formulations were subjected to a taste masking evaluation and a short-term stability study. The results demonstrated that, in comparison to the pure drug, the proportion of drug released from each of the prepared FDTs considerably increased. Results of the stability studies showed that the chosen drug formulations remained stable throughout the storage period | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Olmesartan Medoxomil |2 NLM | |
| 650 | 7 | |a 6M97XTV3HD |2 NLM | |
| 650 | 7 | |a Surface-Active Agents |2 NLM | |
| 650 | 7 | |a Polymers |2 NLM | |
| 650 | 7 | |a Poloxamer |2 NLM | |
| 650 | 7 | |a 106392-12-5 |2 NLM | |
| 650 | 7 | |a Pulmonary Surfactants |2 NLM | |
| 650 | 7 | |a Tablets |2 NLM | |
| 700 | 1 | |a Elbortokaly, Heba M |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamed, Magdy I |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Mahallawi, Abdulaziz M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pakistan journal of pharmaceutical sciences |d 1988 |g 35(2022), 6 vom: 15. Nov., Seite 1481-1493 |w (DE-627)NLM09369900X |x 1011-601X |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2022 |g number:6 |g day:15 |g month:11 |g pages:1481-1493 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2022 |e 6 |b 15 |c 11 |h 1481-1493 | ||